Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
COVID-19 and Cancer CareIrene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
Related Videos
Mehdi Hamadani, MD: In My Experience Question 1
Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?
Recorded April 21, 2020.
Saad Z. Usmani, MD: In My Experience Question 4
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?
Recorded April 24, 2020.
William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic
William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and review...
Laura C. Michaelis, MD: In My Experience Question 4
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24,...
Derek Raghavan, MD, PhD, on COVID-19 and Cancer Care: The View From North Carolina
Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, and a member of The ASCO Post Editorial Board, discusses the ways in which COVID-19 has affecte...
